Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all

Roland P Kuiper; Patricia G Hoogeveen; Reno Bladergroen; Freerk van Dijk; Edwin Sonneveld; Frank N van Leeuwen; Judith Boer; Irina Sergeeva; Harma Feitsma; Monique L den Boer

doi:10.1111/bjh.17744

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all

Roland P Kuiper, Patricia G Hoogeveen, Reno Bladergroen, Freerk van Dijk, Edwin Sonneveld, Frank N van Leeuwen, Judith Boer, Irina Sergeeva, Harma Feitsma, Monique L den Boer

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

Original language	English
Pages (from-to)	888-892
Number of pages	5
Journal	British journal of haematology
Volume	194
Issue number	5
DOIs	https://doi.org/10.1111/bjh.17744
Publication status	Published - Sep 2021

Keywords

Child
Gene Deletion
Humans
Neoplasm, Residual/diagnosis
Oncogene Fusion
Polymerase Chain Reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis

Access to Document

10.1111/bjh.17744

Cite this

Kuiper, R. P., Hoogeveen, P. G., Bladergroen, R., van Dijk, F., Sonneveld, E., van Leeuwen, F. N., Boer, J., Sergeeva, I., Feitsma, H., & den Boer, M. L. (2021). Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all. British journal of haematology, 194(5), 888-892. https://doi.org/10.1111/bjh.17744

@article{b760610b680d41b79dc144eebc0a75bb,

title = "Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all",

abstract = "Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.",

keywords = "Child, Gene Deletion, Humans, Neoplasm, Residual/diagnosis, Oncogene Fusion, Polymerase Chain Reaction, Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis",

author = "Kuiper, {Roland P} and Hoogeveen, {Patricia G} and Reno Bladergroen and {van Dijk}, Freerk and Edwin Sonneveld and {van Leeuwen}, {Frank N} and Judith Boer and Irina Sergeeva and Harma Feitsma and {den Boer}, {Monique L}",

note = "{\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2021",

month = sep,

doi = "10.1111/bjh.17744",

language = "English",

volume = "194",

pages = "888--892",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

Kuiper, RP, Hoogeveen, PG, Bladergroen, R, van Dijk, F, Sonneveld, E, van Leeuwen, FN , Boer, J, Sergeeva, I, Feitsma, H & den Boer, ML 2021, 'Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all', British journal of haematology, vol. 194, no. 5, pp. 888-892. https://doi.org/10.1111/bjh.17744

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all : towards MRD for all. / Kuiper, Roland P; Hoogeveen, Patricia G; Bladergroen, Reno et al.

In: British journal of haematology, Vol. 194, No. 5, 09.2021, p. 888-892.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all

T2 - towards MRD for all

AU - Kuiper, Roland P

AU - Hoogeveen, Patricia G

AU - Bladergroen, Reno

AU - van Dijk, Freerk

AU - Sonneveld, Edwin

AU - van Leeuwen, Frank N

AU - Boer, Judith

AU - Sergeeva, Irina

AU - Feitsma, Harma

AU - den Boer, Monique L

PY - 2021/9

Y1 - 2021/9

N2 - Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

AB - Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

KW - Child

KW - Gene Deletion

KW - Humans

KW - Neoplasm, Residual/diagnosis

KW - Oncogene Fusion

KW - Polymerase Chain Reaction

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85111631657&partnerID=8YFLogxK

U2 - 10.1111/bjh.17744

DO - 10.1111/bjh.17744

M3 - Article

C2 - 34337744

VL - 194

SP - 888

EP - 892

JO - British journal of haematology

JF - British journal of haematology

SN - 0007-1048

IS - 5

ER -

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all

Abstract

Keywords

Access to Document

Fingerprint

Cite this